News - Appointments

James Summers, a neuroscience expert, has joined the board of Mission Therapeutics Ltd as an independent member to help the UK company develop its small molecule drugs for neurodegenerative disorders, mitochondrial diseases and fibrosis.

Amy Pott, a pharma executive with experience in public healthcare, has joined Swedish Orphan Biovitrum AB (Sobi) to lead its North American operations with a focus on commercialising medicines for rare diseases.

The Swedish biotech Medivir AB has appointed Magnus Christensen as its new chief financial officer, effective 12 August.

Andrea van Elsas, an immuno-oncology expert who directed some of the earliest research on pembrolizumab, has joined the supervisory board of DCprime BV to help oversee the company’s relapse vaccines which are intended to delay the recurrence of disease.

David Kaufman, chief medical officer at the Bill & Melinda Gates Medical Research Institute, has joined the board of directors of Hookipa Pharma Inc to help guide development of its immunotherapeutics for infectious diseases and cancers.

Alkermes Plc has appointed the former Celgene Corp executive C. Todd Nichols as its new senior vice president for sales and marketing to help commercialise its portfolio of medicines for chronic diseases.

Giles Campion, a pharmaceutical industry veteran, has been appointed head of research and development and chief medical officer at Silence Therapeutics Plc, effective 1 June. In this role he will help manage the company’s early-stage portfolio of RNA interference (RNAi) medicines.

Zealand Pharma A/S has appointed Emmanuel Dulac as chief executive officer, effective 22 April, to lead the commercialisation of its peptide-based medicines.